CA3005013C - Fviii peptides and their use in tolerising haemophiliacs - Google Patents

Fviii peptides and their use in tolerising haemophiliacs Download PDF

Info

Publication number
CA3005013C
CA3005013C CA3005013A CA3005013A CA3005013C CA 3005013 C CA3005013 C CA 3005013C CA 3005013 A CA3005013 A CA 3005013A CA 3005013 A CA3005013 A CA 3005013A CA 3005013 C CA3005013 C CA 3005013C
Authority
CA
Canada
Prior art keywords
peptide
peptides
fviii
factor viii
haemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3005013A
Other languages
English (en)
French (fr)
Other versions
CA3005013A1 (en
Inventor
David Wraith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worg Pharmaceuticals Zhejiang Co Ltd
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of CA3005013A1 publication Critical patent/CA3005013A1/en
Application granted granted Critical
Publication of CA3005013C publication Critical patent/CA3005013C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3005013A 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs Active CA3005013C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
GB0723712.6 2007-12-04
CA2707559A CA2707559C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2707559A Division CA2707559C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Publications (2)

Publication Number Publication Date
CA3005013A1 CA3005013A1 (en) 2009-06-11
CA3005013C true CA3005013C (en) 2021-11-16

Family

ID=38982965

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3005013A Active CA3005013C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs
CA2707559A Active CA2707559C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2707559A Active CA2707559C (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Country Status (25)

Country Link
US (1) US8445448B2 (https=)
EP (1) EP2227488B3 (https=)
JP (2) JP5501245B2 (https=)
KR (1) KR101519840B1 (https=)
CN (2) CN101889024B (https=)
AU (1) AU2008332968B2 (https=)
BR (1) BRPI0820143A2 (https=)
CA (2) CA3005013C (https=)
CY (1) CY1115168T1 (https=)
DK (1) DK2227488T6 (https=)
EA (1) EA019370B1 (https=)
EC (1) ECSP10010327A (https=)
ES (1) ES2458315T7 (https=)
GB (1) GB0723712D0 (https=)
HR (1) HRP20140344T4 (https=)
IL (1) IL205780A (https=)
MX (1) MX2010006084A (https=)
MY (1) MY150995A (https=)
NZ (1) NZ585217A (https=)
PL (1) PL2227488T6 (https=)
PT (1) PT2227488E (https=)
SI (1) SI2227488T1 (https=)
UA (1) UA101003C2 (https=)
WO (1) WO2009071886A1 (https=)
ZA (1) ZA201002997B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102764425B (zh) 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
EP2300497B1 (en) * 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2765657A1 (en) * 2009-06-16 2010-12-23 Tokai University Anti-gram-negative bacteria agent
EP2632479B1 (en) * 2010-10-27 2017-06-14 Baxalta GmbH Fviii peptides for immune tolerance induction and immunodiagnostics
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
EA036483B1 (ru) * 2012-11-12 2020-11-16 Эпитоп Интернэшнл Нв Пептиды, способные индуцировать толерантность к рекомбинантному fviii, содержащая их композиция, их применение и способ лечения гемофилии
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE902211A1 (en) * 1989-06-20 1991-01-16 Scripps Clinic Res The phospholipid binding domain of factor viii
WO1998031394A2 (en) * 1997-01-22 1998-07-23 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment
CN102764425B (zh) * 2000-08-21 2015-11-25 阿皮托普技术(布里斯托尔)有限公司 肽选择方法
AU2002249779A1 (en) * 2000-12-01 2002-08-12 Regents Of The University Of Minnesota Method to treat hemophilia
CN100522242C (zh) * 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2003087161A1 (en) 2002-04-18 2003-10-23 Merck Patent Gmbh Modified factor viii
HUE027902T2 (en) * 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Also Published As

Publication number Publication date
NZ585217A (en) 2012-11-30
DK2227488T6 (en) 2015-02-16
GB0723712D0 (en) 2008-01-16
JP5501245B2 (ja) 2014-05-21
IL205780A0 (en) 2010-11-30
EA019370B1 (ru) 2014-03-31
ES2458315T3 (es) 2014-04-30
WO2009071886A1 (en) 2009-06-11
CA3005013A1 (en) 2009-06-11
KR101519840B1 (ko) 2015-05-18
EP2227488A1 (en) 2010-09-15
CA2707559A1 (en) 2009-06-11
AU2008332968B2 (en) 2014-03-20
ECSP10010327A (es) 2010-09-30
PL2227488T6 (pl) 2015-04-30
SI2227488T1 (sl) 2014-06-30
US8445448B2 (en) 2013-05-21
MY150995A (en) 2014-03-31
MX2010006084A (es) 2010-06-23
EP2227488B3 (en) 2014-11-19
ES2458315T7 (es) 2015-02-18
JP6063402B2 (ja) 2017-01-18
US20100323966A1 (en) 2010-12-23
PT2227488E (pt) 2014-04-21
PL2227488T3 (pl) 2014-07-31
CN103709234B (zh) 2017-01-18
JP2011505414A (ja) 2011-02-24
HRP20140344T1 (en) 2014-05-09
HK1144292A1 (en) 2011-02-11
AU2008332968A1 (en) 2009-06-11
BRPI0820143A2 (pt) 2015-05-12
KR20100087346A (ko) 2010-08-04
EP2227488B1 (en) 2014-01-22
IL205780A (en) 2015-06-30
EA201070681A1 (ru) 2010-10-29
CY1115168T1 (el) 2016-12-14
HRP20140344T4 (hr) 2015-07-31
CN103709234A (zh) 2014-04-09
ZA201002997B (en) 2011-07-27
JP2014088440A (ja) 2014-05-15
CA2707559C (en) 2018-07-03
UA101003C2 (uk) 2013-02-25
CN101889024B (zh) 2014-04-23
DK2227488T3 (da) 2014-04-22
CN101889024A (zh) 2010-11-17

Similar Documents

Publication Publication Date Title
CA3005013C (en) Fviii peptides and their use in tolerising haemophiliacs
US8703705B2 (en) Modified factor VIII peptides
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180515

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260114

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260316